Back to results
US 2023/0148019 A1Published application
Use of ultrarapid acting insulin
AssigneeMannKind Corporation
InventorsAnders Hasager Boss, Richard Petrucci, Campbell Howard, Alfred Mann
Life of this patent
Estimating the term…
Abstract
Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
Claims20
A method of treating diabetes in a patient currently using a prandial injected insulin, said method comprising replacing said prandial injected insulin with an inhaled formulation comprising a recombinant human insulin and a diketopiperazine.
Dependencies are inferred from the claim text.